Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Company news frequently centers on clinical trial milestones, regulatory interactions and scientific recognition related to hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other conditions driven by dysregulated aldosterone.
News updates from Mineralys describe progress across a broad clinical program. These include topline and subgroup results from the pivotal Launch-HTN Phase 3 trial in uncontrolled or treatment-resistant hypertension, data from the Advance-HTN trial, and long-term follow-up in the Transform-HTN open-label extension. Additional coverage highlights Phase 2 studies such as Explore-CKD, which evaluated lorundrostat in participants with hypertension, CKD and albuminuria, and Explore-OSA, a trial in overweight or obese adults with moderate-to-severe OSA and hypertension.
Investors and observers can also find announcements about regulatory steps, such as plans for and filing of a New Drug Application (NDA) for lorundrostat with the U.S. Food and Drug Administration, as well as public equity offerings and other financing activities disclosed in SEC filings and press releases. Mineralys regularly reports on participation in major medical and scientific meetings, where data from Launch-HTN and Explore-CKD have been featured in sessions and roundups by organizations such as the American Society of Nephrology and the Journal of the American Medical Association.
This news feed aggregates these developments so readers can follow Mineralys Therapeutics’ clinical, regulatory, financial and corporate communications over time, with a particular focus on the evolving evidence base for lorundrostat in hypertension and related comorbidities.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focusing on developing medicines for hypertension, chronic kidney disease (CKD), and aldosterone-related disorders, has announced its plan to release second quarter 2024 financial results on Tuesday, August 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can access the call via domestic (1-877-407-9127) or international (1-201-689-8574) phone numbers, or through a webcast link available on the company's Investor Relations webpage.
Mineralys Therapeutics (NASDAQ: MLYS) has appointed Dr. Alexander M. Gold to its Board of Directors, effective June 13, 2024. Dr. Gold, a cardiologist with over 20 years of experience, has a strong background in developing and commercializing new therapies. His previous roles include Chief Medical Officer at Sanifit-CSL and Senior Vice President at Portola Pharmaceuticals. Concurrently, Dr. Olivier Litzka has resigned from the Board to focus on his venture capital investments. Mineralys is currently advancing the late-stage clinical development of lorundrostat, aimed at treating hypertension and other cardiorenal metabolic disorders.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL from June 10-13, 2024. The company's management will engage in a fireside chat on June 11, 2024, at 4:00 pm EDT. The discussion will be webcast live and accessible through the Investor Relations section on the Mineralys website, with a replay available for 90 days.
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, reported its first quarter 2024 financial results and provided a corporate update. The company is focused on developing medicines targeting hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. Their ongoing clinical trials for lorundrostat are expected to deliver topline data in Q4 2024 and 2H 2025. Mineralys also highlighted its strengthened balance sheet after completing a private placement financing in Q1 2024, providing them with sufficient funds until 2026.
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities Health Care Conference. The company focuses on developing medicines for hypertension, chronic kidney disease, and diseases driven by dysregulated aldosterone. The event will take place in Las Vegas on May 14-16, 2024. Investors can access a live webcast and replay of the chat on the company's website.
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will announce its first quarter 2024 financial results on May 9, 2024. The company focuses on developing medicines for hypertension, chronic kidney disease, and other diseases related to dysregulated aldosterone. The conference call will be hosted at 8:30 a.m. ET, offering dial-in and webcast options for participants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.